Analysts think CRVO stock price could increase by 451%
Dec 26, 2024, 12:25 PM
4.05%
What does CRVO do
CervoMed, a Boston-based biotechnology company with 8 employees, focuses on developing neflamapimod for neurodegenerative diseases and is conducting the RewinD-LB Phase 2b trial for dementia with Lewy bodies. The drug aims to modify disease processes and improve synaptic dysfunction.
5 analysts think CRVO stock price will increase by 451.35%. The current median analyst target is $12.24 compared to a current stock price of $2.22. The lowest analysts target is $4.04 and the highest analyst target is $57.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.